CB Labs Tesamorelin 20mg x 3ml

Description

 

Classification

Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue. It stimulates the pituitary gland to release endogenous growth hormone, which subsequently increases circulating insulin-like growth factor-1 (IGF-1). An authorised tesamorelin medicine, EGRIFTA, is indicated in the United States for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated as a general weight-loss treatment. 

What is CB Labs Tesamorelin 20mg x 3ml?

CB Labs Tesamorelin 20mg x 3ml is presented as an injectable product containing tesamorelin. Tesamorelin is a synthetic analogue of naturally occurring growth-hormone-releasing hormone and is designed to stimulate the body’s own growth-hormone pathway.

The “20mg x 3ml” description refers to the stated amount and volume of the particular product. It should not be confused with the dosing strengths of authorised EGRIFTA formulations, which have different concentrations and preparation requirements. 

Dosage

Tesamorelin dosing is formulation-specific and medically supervised. The authorised EGRIFTA SV formulation has a recommended dose of 1.4mg once daily, but this dosing information applies specifically to that approved 2mg-per-vial formulation and should not be applied to a CB Labs 20mg x 3ml product. 

For safety:

• Do not calculate a dose from the total 20mg content alone.
• Do not inject the entire contents as a single dose.
• Follow instructions from a qualified prescriber for the exact formulation.
• Do not change the dose without professional advice.
• Never use an injectable product if its identity, concentration or sterility is uncertain.

How Does CB Labs Tesamorelin Work?

Tesamorelin acts similarly to endogenous growth-hormone-releasing hormone. It stimulates receptors involved in the pituitary growth-hormone pathway, increasing the release of growth hormone. Growth hormone then promotes production of IGF-1 and influences several metabolic processes.

In clinical studies of its approved indication, this pathway has been associated with reductions in visceral abdominal adipose tissue. However, tesamorelin is not simply a general-purpose fat-loss medicine, and the approved prescribing information specifically states that it is not indicated for weight-management treatment.

Benefits 

For its authorised clinical indication, tesamorelin may help reduce excess visceral abdominal fat in eligible adults with HIV-associated lipodystrophy.

Potential therapeutic effects include:

• Reduction in visceral abdominal adipose tissue.
• Stimulation of the body’s growth-hormone pathway.
• Increased IGF-1 production.
• Improvement in body-fat distribution in appropriate patients.

These effects should not be interpreted as guaranteed weight loss or bodybuilding benefits. The FDA prescribing information specifically states that EGRIFTA is not indicated for weight-loss management because its effect is considered weight-neutral. 

When Should You Take CB Labs Tesamorelin?

Authorised tesamorelin formulations are administered subcutaneously, with the specific schedule determined by the formulation and prescribing information. EGRIFTA SV, for example, is administered once daily into the abdomen, with injection sites rotated. 

Because CB Labs 20mg x 3ml may have a different formulation and concentration, its administration should not be inferred from the EGRIFTA instructions. A healthcare professional should confirm the appropriate method and schedule.

When Should You Not Take CB Labs Tesamorelin?

Tesamorelin may be unsuitable for people with particular medical conditions. The authorised EGRIFTA prescribing information contraindicates treatment in patients with:

• Active malignancy.
• Disruption of the hypothalamic-pituitary axis.
• Certain previous pituitary disorders, surgery, irradiation or head trauma.
• Known hypersensitivity to tesamorelin or relevant ingredients. 

Medical assessment is also particularly important for people with diabetes, pre-existing cancer, cardiovascular concerns or disorders affecting the pituitary or endocrine system.

What is the Mechanism of CB Labs Tesamorelin?

Tesamorelin is a GHRH analogue that stimulates the pituitary gland to release growth hormone. Growth hormone then influences the liver and other tissues to increase IGF-1 production.

This growth-hormone/IGF-1 pathway can influence fat metabolism and body composition. Because the pathway has effects throughout the body, monitoring may be necessary during medically supervised treatment.

Uses of CB Labs Tesamorelin

The established clinical use of authorised tesamorelin is specific. EGRIFTA is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. 

Tesamorelin should not be promoted as an approved treatment for:

• General weight loss.
• Cosmetic fat reduction.
• Muscle building.
• Athletic performance enhancement.
• Anti-ageing.

Use outside an authorised indication should only be considered within appropriate specialist medical care or legitimate clinical research.

Warnings and Precautions

Tesamorelin can influence growth-hormone and IGF-1 levels and therefore requires appropriate medical monitoring. Important concerns include elevated IGF-1, glucose intolerance, fluid retention and possible hypersensitivity reactions.

Patients should inform their healthcare professional if they have:

• Diabetes or impaired glucose tolerance.
• A history of cancer.
• Pituitary or hypothalamic disorders.
• Cardiovascular disease.
• Severe or unexplained swelling.
• Previous allergic reactions to peptide medicines.

Long-term cardiovascular safety has not been established for authorised tesamorelin treatment. 

Side Effects of Tesamorelin

Reported adverse reactions with authorised tesamorelin treatment include:

• Injection-site reactions.
• Joint pain.
• Muscle pain.
• Swelling or fluid retention.
• Increased blood glucose.
• Headache.
• Itching or rash.

Serious hypersensitivity reactions can occur. Patients should seek urgent medical attention if they develop significant swelling, breathing difficulty, widespread rash or other symptoms of a severe allergic reaction.

Storage for CB Labs Tesamorelin 20mg x 3ml

Storage requirements depend on the exact formulation. Authorised tesamorelin products have specific refrigeration, preparation and handling requirements, and different formulations are not interchangeable.

For the CB Labs product, follow the manufacturer’s verified storage instructions. Do not use an injectable preparation that appears contaminated, damaged, discoloured or otherwise unsuitable.

Where to Buy CB Labs Tesamorelin 20mg x 3ml?

To get CB Labs Tesamorelin 20mg x 3ml  online, go to Steroid Sanctuary today to get the best deal on this medicine.

 

Frequently Asked Questions

1. What is tesamorelin?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone that stimulates the body’s growth-hormone pathway and increases IGF-1 production.

2. What is authorised tesamorelin used for?

EGRIFTA is authorised in the US for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not indicated for general weight-loss management.

3. Is tesamorelin the same as human growth hormone?

No. Tesamorelin stimulates the body’s own release of growth hormone, whereas somatropin is recombinant human growth hormone itself.

4. Does the 20mg amount mean one 20mg injection?

No. The total amount stated on a product should not be interpreted as a recommended individual dose. Authorised tesamorelin formulations use substantially different dosing and preparation instructions. 

5. Does tesamorelin cause weight loss?

Tesamorelin’s authorised indication concerns reduction of visceral abdominal fat in a specific patient population. The FDA prescribing information specifically states that it is not indicated for weight-loss management and has a weight-neutral effect.